We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
OVALEAP (Theramex Australia Pty Ltd)
Product name
OVALEAP
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
187 (255 working days)
Active ingredients
follitropin alfa
Registration type
NCE/NBE
Indication
OVALEAP (solution for injection) is indicated for:
- The treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.
- For controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.
- OVALEAP is indicated with concomitant human chorionic gonadotrophin (hCG) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hCG alone is ineffective.